|Cancer Therapeutics & Partnering Summit|
Oncology Partnering & Deal-Making
Complementary & Companion Diagnostics in Oncology
The field of Cancer Immunotherapy is of continuously escalating significance, as well as scientifically, economically and socially important. The Cancer Immunotherapy Conference on September 28-29, 2017 in San Diego, CA allows scientists, clinicians, and R&D experts to meet together and discuss the latest therapeutic, preventive and diagnostic developments in the field.
The immune system plays a central role not only in fighting infections, but also in many other diseases and medical conditions including cancer. The study of the immune system has lead to significant findings in many fields of medicine and biology and has resulted in the discovery of novel and unique substances and reagents that are now widely used for diagnosis, evaluation and therapy of different malignant diseases. The development of prophylactic and therapeutic vaccines, as well as innovative combinatorial immunotherapeutic approaches for patients with cancer has substantially decreased mortality and morbidity and improved the life, life expectancy, and the well being of the millions of patients with malignant diseases.
We hope to see you there!
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
ACEA Biosciences, Inc. is a pioneer in the development and commercialization of highperformance microelectronic systems for cell-based assays. ACEA’s xCELLigence® systems are widely used in academic labs, government institutions, biotech and pharma companies around the world to study cell adhesion, cell migration/invasion, GPCR/RTK signaling, cell proliferation and compound/cell/viral-mediated cytotoxicity.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.